Lovastatin therapy in nephrotic hyperlipidemia

Effects on lipoprotein metabolism

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

The nephrotic syndrome is characterized by proteinuria, hypoalbuminemia, and hypercholesterolemia. Hypertriglyceridemia often is present as well. In this study, the kinetics of plasma lipoproteins were investigated in four patients with nephrotic hyperlipidemia, and repeat studies were carried out in three of these patients during therapy with lovastatin. Before lovastatin therapy, the patients had an extremely delayed catabolism of very low density lipoproteins (VLDL) without evidence of overproduction of lipoproteins in this fraction. Three of four patients had elevated levels of low density lipoprotein (LDL) that were due mainly to increased production rates for LDL. In the three patients treated with lovastatin, the drug therapy lowered plasma concentrations of total cholesterol, triglycerides, VLDL-cholesterol, and LDL-cholesterol, and raised high density lipoprotein (HDL)-cholesterol. Lovastatin therapy decreased VLDL-triglycerides primarily by enhancing their catabolism, and lowered LDL-cholesterol levels mainly by reducing input rates for LDL. Overall, lovastatin appears to be an effective drug for the treatment of hyperlipidemia in the nephrotic syndrome.

Original languageEnglish (US)
Pages (from-to)1160-1168
Number of pages9
JournalKidney International
Volume33
Issue number6
StatePublished - 1988

Fingerprint

Lovastatin
Hyperlipidemias
Lipoproteins
LDL Lipoproteins
Nephrotic Syndrome
LDL Cholesterol
Therapeutics
VLDL Cholesterol
Hypoalbuminemia
VLDL Lipoproteins
Hypertriglyceridemia
Hypercholesterolemia
Proteinuria
HDL Cholesterol
Triglycerides
Cholesterol
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Nephrology

Cite this

Lovastatin therapy in nephrotic hyperlipidemia : Effects on lipoprotein metabolism. / Vega, Gloria L; Grundy, Scott M.

In: Kidney International, Vol. 33, No. 6, 1988, p. 1160-1168.

Research output: Contribution to journalArticle

@article{c4412e565d8047d888c8de0eb3cabfe6,
title = "Lovastatin therapy in nephrotic hyperlipidemia: Effects on lipoprotein metabolism",
abstract = "The nephrotic syndrome is characterized by proteinuria, hypoalbuminemia, and hypercholesterolemia. Hypertriglyceridemia often is present as well. In this study, the kinetics of plasma lipoproteins were investigated in four patients with nephrotic hyperlipidemia, and repeat studies were carried out in three of these patients during therapy with lovastatin. Before lovastatin therapy, the patients had an extremely delayed catabolism of very low density lipoproteins (VLDL) without evidence of overproduction of lipoproteins in this fraction. Three of four patients had elevated levels of low density lipoprotein (LDL) that were due mainly to increased production rates for LDL. In the three patients treated with lovastatin, the drug therapy lowered plasma concentrations of total cholesterol, triglycerides, VLDL-cholesterol, and LDL-cholesterol, and raised high density lipoprotein (HDL)-cholesterol. Lovastatin therapy decreased VLDL-triglycerides primarily by enhancing their catabolism, and lowered LDL-cholesterol levels mainly by reducing input rates for LDL. Overall, lovastatin appears to be an effective drug for the treatment of hyperlipidemia in the nephrotic syndrome.",
author = "Vega, {Gloria L} and Grundy, {Scott M}",
year = "1988",
language = "English (US)",
volume = "33",
pages = "1160--1168",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Lovastatin therapy in nephrotic hyperlipidemia

T2 - Effects on lipoprotein metabolism

AU - Vega, Gloria L

AU - Grundy, Scott M

PY - 1988

Y1 - 1988

N2 - The nephrotic syndrome is characterized by proteinuria, hypoalbuminemia, and hypercholesterolemia. Hypertriglyceridemia often is present as well. In this study, the kinetics of plasma lipoproteins were investigated in four patients with nephrotic hyperlipidemia, and repeat studies were carried out in three of these patients during therapy with lovastatin. Before lovastatin therapy, the patients had an extremely delayed catabolism of very low density lipoproteins (VLDL) without evidence of overproduction of lipoproteins in this fraction. Three of four patients had elevated levels of low density lipoprotein (LDL) that were due mainly to increased production rates for LDL. In the three patients treated with lovastatin, the drug therapy lowered plasma concentrations of total cholesterol, triglycerides, VLDL-cholesterol, and LDL-cholesterol, and raised high density lipoprotein (HDL)-cholesterol. Lovastatin therapy decreased VLDL-triglycerides primarily by enhancing their catabolism, and lowered LDL-cholesterol levels mainly by reducing input rates for LDL. Overall, lovastatin appears to be an effective drug for the treatment of hyperlipidemia in the nephrotic syndrome.

AB - The nephrotic syndrome is characterized by proteinuria, hypoalbuminemia, and hypercholesterolemia. Hypertriglyceridemia often is present as well. In this study, the kinetics of plasma lipoproteins were investigated in four patients with nephrotic hyperlipidemia, and repeat studies were carried out in three of these patients during therapy with lovastatin. Before lovastatin therapy, the patients had an extremely delayed catabolism of very low density lipoproteins (VLDL) without evidence of overproduction of lipoproteins in this fraction. Three of four patients had elevated levels of low density lipoprotein (LDL) that were due mainly to increased production rates for LDL. In the three patients treated with lovastatin, the drug therapy lowered plasma concentrations of total cholesterol, triglycerides, VLDL-cholesterol, and LDL-cholesterol, and raised high density lipoprotein (HDL)-cholesterol. Lovastatin therapy decreased VLDL-triglycerides primarily by enhancing their catabolism, and lowered LDL-cholesterol levels mainly by reducing input rates for LDL. Overall, lovastatin appears to be an effective drug for the treatment of hyperlipidemia in the nephrotic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0023948210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023948210&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 1160

EP - 1168

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -